// App-Quantinova.ai

4072 : Analysis of clinical BRCA1/2 reversions identifies hotspot mutations and predicted neoantigens associated with therapy resistance

Researchers

Presenter

  • Stephen Pettitt

Principal Investigators

  • Jessica Frankum

  • Marco Punta

  • Stefano Lise

  • John Alexander

  • Yi Chen

  • Syed Haider

  • Andrew N. Tutt

  • Christopher J. Lord

Medical Centers

  • Institute for Cancer Research, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Gynaecological cancer

Biomarkers

  • Breast cancer type 2 susceptibility protein

  • BRCA mutation

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved